| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ernexa Therapeutics Inc. (ERNA) has 0 insiders with recent SEC Form 4 filings, including 40 buys and 0 sells. ERNA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 17, 2016 | Krishnan Ram | CEO | Buy | 3,000 | $4.85 | $14,561.53 | +7.0% | |
| Jun 16, 2016 | Miller Dave Brian | SVP Marketing | Buy | 40,000 | $0.12 | $4,664.00 | +6.5% | |
| Jun 13, 2016 | Wolff Allen | CFO And EVP | Buy | 15,000 | $0.12 | $1,792.50 | +18.6% | |
| Jun 8, 2016 | Miller Dave Brian | SVP Marketing | Buy | 30,000 | $0.12 | $3,600.00 | +27.3% | |
| May 26, 2016 | Yanover Paul | Director | Buy | 65,000 | $0.17 | $10,897.61 | +3.8% | |
| May 26, 2016 | Krishnan Ram | CEO | Buy | 50,000 | $0.16 | $7,998.49 | +7.5% | |
| May 24, 2016 | Miller Dave Brian | SVP Marketing | Buy | 20,000 | $0.16 | $3,200.00 | +22.2% | |
| May 17, 2016 | Miller Dave Brian | SVP Marketing | Buy | 50,000 | $0.17 | $8,433.00 | +20.0% | |
| Mar 16, 2016 | Wolff Allen | CFO And EVP | Buy | 15,000 | $0.18 | $2,771.00 | +7.1% | |
| Mar 16, 2016 | Krishnan Ram | CEO | Buy | 15,000 | $0.19 | $2,848.50 | +18.8% |